• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Valeant Pharmaceuticals

Shares soar for InVivo after spinal cord study update | Medtech Wall Street news for the week of November 17, 2014

November 20, 2014 By MassDevice Leave a Comment

InVivo shares soar on spinal cord study update

November 13, 2014 by Val Kennedy

Filed Under: News Well, Wall Street Beat Tagged With: Actavis, Allergan, InVivo Therapeutics, National Venture Capital Assn. (NVCA), Pershing Square Capital Management, PricewaterhouseCoopers (PwC), Thomson Reuters, Valeant Pharmaceuticals

MDT prepares $10B worth of bonds to help fund its $43B acquisition of COV | The week in medtech M&A

November 19, 2014 By MassDevice Leave a Comment

Report: Medtronic readies $10B bond flotation for Covidien deal

November 17, 2014 by Brad Perriello

Filed Under: Mergers & Acquisitions, News Well Tagged With: Actavis, Allergan, Covidien, Pershing Square Capital Management, Philips, PricewaterhouseCoopers (PwC), Valeant Pharmaceuticals

Ackman supports Allergan’s $66B sale to Actavis

November 18, 2014 By MassDevice Leave a Comment

Ackman supports Allergan's $66B sale to Actavis

Filed Under: Mergers & Acquisitions, News Well Tagged With: Actavis, Allergan, Pershing Square Capital Management, Valeant Pharmaceuticals

UPDATE: Actavis trumps Valeant with $66B offer for Allergan

November 17, 2014 By Brad Perriello Leave a Comment

UPDATE: Actavis trumps Valeant with $66B offer for Allergan

Filed Under: Mergers & Acquisitions, News Well, Pharmaceutical, Wall Street Beat Tagged With: Actavis, Allergan, Pershing Square Capital Management, Valeant Pharmaceuticals

Source: Allergan near $66B buyout to escape Valeant, Ackman

November 17, 2014 By MassDevice Leave a Comment

Source: Allergan near $66B buyout to escape Valeant, Ackman

Filed Under: Mergers & Acquisitions, News Well, Pharmaceutical Tagged With: Actavis, Allergan, Pershing Square Capital Management, Valeant Pharmaceuticals

Report: Actavis may buy Allergan for at least $60 billion

November 12, 2014 By MassDevice Leave a Comment

Report: Actavis may buy Allergan for at least $60 billion

Filed Under: Mergers & Acquisitions, News Well, Pharmaceutical, Wall Street Beat Tagged With: Actavis, Allergan, Pershing Square Capital Management, Valeant Pharmaceuticals

Medtronic inks package of loans worth more than $16 billion to back its $43 billion acquisition of Covidien | The week in medtech M&A

November 12, 2014 By MassDevice Leave a Comment

Medtronic inks $16B loan package for Covidien buyout

November 10, 2014 by Brad Perriello

Filed Under: Mergers & Acquisitions, News Well Tagged With: Allergan, Covidien, Pershing Square Capital Management, Salix Pharmaceuticals, Tornier Inc., Valeant Pharmaceuticals, wrightmedical, Ximedica LLC

Salix inventory snafu sinks deal with Allergan

November 7, 2014 By MassDevice Leave a Comment

Salix inventory issues sink deal with Allergan

Filed Under: Mergers & Acquisitions, News Well, Pharmaceutical, Wall Street Beat Tagged With: Allergan, Pershing Square Capital Management, Salix Pharmaceuticals, Valeant Pharmaceuticals

Allergan in talks with 3rd-party acquirer

November 6, 2014 By MassDevice Leave a Comment

Allergan in talks with 3rd-party acquirer

Filed Under: Mergers & Acquisitions, News Well, Pharmaceutical Tagged With: Actavis, Allergan, Pershing Square Capital Management, Valeant Pharmaceuticals

Court leaves door open for Ackman’s vote at Allergan meeting

November 4, 2014 By MassDevice Leave a Comment

Court leaves door open for Ackman's vote at Allergan meeting

Ackman (Reuters/Eduardo Munoz).
Click to enlarge.

Filed Under: Mergers & Acquisitions, News Well, Pharmaceutical Tagged With: Allergan, Pershing Square Capital Management, Valeant Pharmaceuticals

Allergan: We’ve been approached by 3rd party about a deal

November 3, 2014 By MassDevice Leave a Comment

Allergan: We've been approached by another party about a deal

Filed Under: Mergers & Acquisitions, News Well, Pharmaceutical Tagged With: Actavis, Allergan, Pershing Square Capital Management, Valeant Pharmaceuticals

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Interim pages omitted …
  • Go to page 9
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS